Jean-michel Livrozet - Academia.edu (original) (raw)

Uploads

Papers by Jean-michel Livrozet

Research paper thumbnail of Hyperglycosylated ferritin in sera of HIV-1-infected patients treated with highly active antiretroviral therapy

AIDS, 2006

Pleiotropic features are attributed to statins and fibrates, and effects on laboratory markers of... more Pleiotropic features are attributed to statins and fibrates, and effects on laboratory markers of HIV disease progression have been claimed. To assess whether statins/fibrates have long-term effects on the immune recovery of patients on virologically effective HAART, a prospective, comparative study was conducted on 267 dyslipidemic patients treated with either statins, fibrates, or on a dietary exercise programme only. Quarterly assessment of CD4 cell counts showed no differences between groups, thus excluding in-vivo negative immunological effects during effective HAART.

Research paper thumbnail of Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

Journal of the International AIDS Society, 2010

Research paper thumbnail of Humoral immune response within the lung in HIV-1 infection

Clinical & Experimental Immunology, 1997

SUMMARY In order to study the humoral immune defences in the respiratory tract during HIV-1 infec... more SUMMARY In order to study the humoral immune defences in the respiratory tract during HIV-1 infection, we measured the levels, local productions and anti-HIV and antibacterial activities of IgG and IgA in the bronchoalveolar lavage fluid (BALF) and serum of 61 adult patients with severe HIV infection and of 56 HIV− controls. Albumin was used as the serum transudation factor. The increase of immunoglobulin levels in the serum of HIV-infected patients was confirmed. The IgG level was also increased in epithelial lining fluid (ELF), whereas the total IgA level was unchanged and secretory IgA (SIgA) level was decreased. The ELF/serum immunoglobulin ratios suggested that the IgG present in ELF resulted mainly from transudation, in contrast to SIgA, which was synthesized locally in controls but greatly diminished in HIV-infected patients. IgG to HIV-1 could be detected in BALF of all the patients, but IgA to HIV-1 only in 30% of patients. BAL IgG reacted more consistently and with a broad...

Research paper thumbnail of A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir …

Clinical infectious …, 2004

The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100... more The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d. regimen and an APV-RTV 1200/200 mg q.d. regimen were studied in a human immunodeficiency virus (HIV)-infected population. The geometric least-square mean ratio (90% confidence interval) of steady-state trough concentrations, compared with that of the amprenavir 1200 mg b.i.d. regimen, was 6.08 (4.94-7.49) for the twice-daily APV-RTV regimen, and it was 4.19 (2.90-6.08) for the daily APV-RTV regimen. The regimens were well tolerated, which supports APV-RTV as an option for twice-daily or daily therapy for HIV. Amprenavir (APV; Agenerase; GlaxoSmithKline) is an HIV protease inhibitor with potent antiretroviral activity [1-3] and a favorable safety [4] and cross-resistance profile [5-7] when administered as part of a combination regimen. Ritonavir (RTV; Norvir; Abbott Laboratories) is frequently coadministered with HIV protease inhibitors at subtherapeutic doses be

Research paper thumbnail of Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome

HIV Medicine, 2008

The effect of starting highly active antiretroviral therapy (HAART) early after the onset of acut... more The effect of starting highly active antiretroviral therapy (HAART) early after the onset of acute retroviral syndrome (ARS) on CD4 and HIV-RNA trends was studied over a 2-year follow-up period.

Research paper thumbnail of Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome

Journal of the International AIDS Society, 2010

Research paper thumbnail of H-28 Atazanavir non boosté en une prise versus deux prises par jour : comparaison des taux résiduels chez 38 patients infecté par le VIH prétraités

Médecine et Maladies Infectieuses, 2009

Research paper thumbnail of A recent increase in AIDS at Lyon University Hospitals: patient characteristics and comparisons with previous years

HIV Medicine, 2006

A 36% increase in the incidence of AIDS was observed in

Research paper thumbnail of Characteristics of patients diagnosed with AIDS shortly after first detection of HIV antibodies in Lyon University hospitals from 1985 to 2001*

HIV Medicine, 2004

A diagnosis of AIDS shortly after the detection of HIV antibodies suggests a long-lasting course ... more A diagnosis of AIDS shortly after the detection of HIV antibodies suggests a long-lasting course of the disease without care. The factors associated with a short delay between the initial HIV-1-positive test and the first AIDS-defining event were identified in 1901 patients from 1985 to 2001 in Lyon University hospitals. A total of 576 individuals (30.3%) had an interval of 3 months between the detection of HIV infection and AIDS. The factors independently associated with a delay of 3 months were: age from 30 to 44 years [odds ratio (OR) 2.5; 95% confidence interval (CI) 1.9-3.2]; age from 45 to 59 years (OR 5.6; 95% CI 3.9-7.8); age ! 60 years (OR 4.5; 95% CI 2.5-8.1), compared to thoseo30 years old; heterosexuality (OR 2.4; 95% CI 1.6-3.4); injection drug use (OR 2.1; 95% CI 1.5-2.7); and other exposures (OR 2.4; 95% CI 1.6-3.4), compared to homosexual exposure; two opportunistic infections at AIDS (OR 1.8; 95% CI 1.4-2.4) compared to one; and Pneumocystis carinii pneumonia as initial AIDS event (OR 2.6; 95% CI 1.8-3.7), compared to Kaposi's sarcoma. These results provide opportunities to refocus local public health interventions to reduce delayed access to care.

Research paper thumbnail of Hyperglycosylated ferritin in sera of HIV-1-infected patients treated with highly active antiretroviral therapy

AIDS, 2006

Pleiotropic features are attributed to statins and fibrates, and effects on laboratory markers of... more Pleiotropic features are attributed to statins and fibrates, and effects on laboratory markers of HIV disease progression have been claimed. To assess whether statins/fibrates have long-term effects on the immune recovery of patients on virologically effective HAART, a prospective, comparative study was conducted on 267 dyslipidemic patients treated with either statins, fibrates, or on a dietary exercise programme only. Quarterly assessment of CD4 cell counts showed no differences between groups, thus excluding in-vivo negative immunological effects during effective HAART.

Research paper thumbnail of Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

Journal of the International AIDS Society, 2010

Research paper thumbnail of Humoral immune response within the lung in HIV-1 infection

Clinical & Experimental Immunology, 1997

SUMMARY In order to study the humoral immune defences in the respiratory tract during HIV-1 infec... more SUMMARY In order to study the humoral immune defences in the respiratory tract during HIV-1 infection, we measured the levels, local productions and anti-HIV and antibacterial activities of IgG and IgA in the bronchoalveolar lavage fluid (BALF) and serum of 61 adult patients with severe HIV infection and of 56 HIV− controls. Albumin was used as the serum transudation factor. The increase of immunoglobulin levels in the serum of HIV-infected patients was confirmed. The IgG level was also increased in epithelial lining fluid (ELF), whereas the total IgA level was unchanged and secretory IgA (SIgA) level was decreased. The ELF/serum immunoglobulin ratios suggested that the IgG present in ELF resulted mainly from transudation, in contrast to SIgA, which was synthesized locally in controls but greatly diminished in HIV-infected patients. IgG to HIV-1 could be detected in BALF of all the patients, but IgA to HIV-1 only in 30% of patients. BAL IgG reacted more consistently and with a broad...

Research paper thumbnail of A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir …

Clinical infectious …, 2004

The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100... more The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d. regimen and an APV-RTV 1200/200 mg q.d. regimen were studied in a human immunodeficiency virus (HIV)-infected population. The geometric least-square mean ratio (90% confidence interval) of steady-state trough concentrations, compared with that of the amprenavir 1200 mg b.i.d. regimen, was 6.08 (4.94-7.49) for the twice-daily APV-RTV regimen, and it was 4.19 (2.90-6.08) for the daily APV-RTV regimen. The regimens were well tolerated, which supports APV-RTV as an option for twice-daily or daily therapy for HIV. Amprenavir (APV; Agenerase; GlaxoSmithKline) is an HIV protease inhibitor with potent antiretroviral activity [1-3] and a favorable safety [4] and cross-resistance profile [5-7] when administered as part of a combination regimen. Ritonavir (RTV; Norvir; Abbott Laboratories) is frequently coadministered with HIV protease inhibitors at subtherapeutic doses be

Research paper thumbnail of Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome

HIV Medicine, 2008

The effect of starting highly active antiretroviral therapy (HAART) early after the onset of acut... more The effect of starting highly active antiretroviral therapy (HAART) early after the onset of acute retroviral syndrome (ARS) on CD4 and HIV-RNA trends was studied over a 2-year follow-up period.

Research paper thumbnail of Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome

Journal of the International AIDS Society, 2010

Research paper thumbnail of H-28 Atazanavir non boosté en une prise versus deux prises par jour : comparaison des taux résiduels chez 38 patients infecté par le VIH prétraités

Médecine et Maladies Infectieuses, 2009

Research paper thumbnail of A recent increase in AIDS at Lyon University Hospitals: patient characteristics and comparisons with previous years

HIV Medicine, 2006

A 36% increase in the incidence of AIDS was observed in

Research paper thumbnail of Characteristics of patients diagnosed with AIDS shortly after first detection of HIV antibodies in Lyon University hospitals from 1985 to 2001*

HIV Medicine, 2004

A diagnosis of AIDS shortly after the detection of HIV antibodies suggests a long-lasting course ... more A diagnosis of AIDS shortly after the detection of HIV antibodies suggests a long-lasting course of the disease without care. The factors associated with a short delay between the initial HIV-1-positive test and the first AIDS-defining event were identified in 1901 patients from 1985 to 2001 in Lyon University hospitals. A total of 576 individuals (30.3%) had an interval of 3 months between the detection of HIV infection and AIDS. The factors independently associated with a delay of 3 months were: age from 30 to 44 years [odds ratio (OR) 2.5; 95% confidence interval (CI) 1.9-3.2]; age from 45 to 59 years (OR 5.6; 95% CI 3.9-7.8); age ! 60 years (OR 4.5; 95% CI 2.5-8.1), compared to thoseo30 years old; heterosexuality (OR 2.4; 95% CI 1.6-3.4); injection drug use (OR 2.1; 95% CI 1.5-2.7); and other exposures (OR 2.4; 95% CI 1.6-3.4), compared to homosexual exposure; two opportunistic infections at AIDS (OR 1.8; 95% CI 1.4-2.4) compared to one; and Pneumocystis carinii pneumonia as initial AIDS event (OR 2.6; 95% CI 1.8-3.7), compared to Kaposi's sarcoma. These results provide opportunities to refocus local public health interventions to reduce delayed access to care.